US Executive Compensation Proxy SEC Filings — October 14, 2026

14-10-2026

Transocean Ltd. (RIG) has called an extraordinary general meeting for November 24, 2026 to seek shareholder approval for its Business Combination with Valaris Limited under a February 9, 2026 Business Combination Agreement. Each Valaris share would be exchanged for 15.235 Transocean shares, with Transocean shareholders and Valaris shareholders expected to own approximately 53% and 47% of the combined company, respectively, on a fully diluted basis. Shareholder approval of the share issuance resolutions and the NYSE 20% share issuance proposal is a condition to completing the transaction.

• · Extraordinary general meeting scheduled for November 24, 2026 at 3:00 p.m. Swiss time at Steinhausen, Switzerland
• · Proxy voting deadline is 4:00 p.m. Eastern Time on November 23, 2026; record date for voting is November 9, 2026
• · Transocean Board unanimously recommends voting FOR all Transocean Resolutions
• · Unless the ordinary share capital increase, capital band, and NYSE 20% share issuance proposal are all approved, none of the resolutions or director elections take effect
• · Six agenda items include share issuances, an NYSE 20% issuance proposal, two director/committee election resolutions, and removal of obsolete Article 38 from the Articles of Association
• · Shareholder approval is a condition to completing the Business Combination

14-10-2026

Valaris Ltd filed a joint proxy statement (DEFM14A) on October 14, 2026 in connection with its proposed Business Combination with Transocean, under which Valaris would become a wholly-owned subsidiary of Transocean and Valaris shareholders would receive Transocean Shares. The filing presents unaudited pro forma combined results showing contract drilling revenues of $3,052 Million for the six months ended June 30, 2026 with net income of $203 Million, versus a pro forma net loss of $3,327 Million and operating loss of $2,048 Million for FY2025, reflecting a mixed earnings picture. Ownership disclosures show BlackRock (11.39%), Famatown Finance (11.28%, party to a shareholder support agreement with Transocean) and Vanguard (9.29%) as the largest Valaris holders.

• · Famatown Finance and affiliates signed a Valaris Shareholder Support Agreement with Transocean on February 9, 2026 agreeing to vote their Valaris Shares in favor of the Business Combination; the agreement does not grant Transocean a voting proxy
• · Valaris shareholders would receive Transocean Shares and be governed by Swiss law and the Transocean Articles if the Business Combination closes
• · If the Business Combination is not consummated, Valaris expects to hold its 2027 Annual General Meeting; shareholder proposals for inclusion in that proxy must be delivered by December 17, 2026
• · Vanguard reported in March 2026 an internal realignment, after which it no longer has or is deemed to have beneficial ownership of the reported shares, and affiliated divisions will report separately
• · Pro forma FY2025 results show a substantial net loss, contrasting with positive pro forma net income in the six months ended June 30, 2026

14-10-2026

Atlassian Corporation's DEF 14A definitive proxy statement, filed October 14, 2026, sets up a virtual Annual Meeting of Stockholders on December 1, 2026. Stockholders will vote on electing 9 directors, ratifying Ernst & Young LLP as auditor for fiscal 2027, and an advisory say-on-pay vote for fiscal 2026 named executive officers. The accompanying CEO letter reports strong fiscal 2026 growth, with total revenue up 26% y/y to $6.6 billion and Cloud revenue reaching $4.4 billion, while noting that the company has not received notice of any other matters to be raised.

• · Annual Meeting to be held virtually on December 1, 2026 at 2:00 p.m. Pacific Time; record date is October 7, 2026
• · Proposal 3 is an advisory say-on-pay vote; for street name holders, brokers are expected to vote only on Proposal 2 absent instructions
• · Fiscal 2026 delivered GAAP operating profitability for the full year
• · Single largest deal in company history was landed in fiscal 2026, with record large customer contracts

14-10-2026

Entera Bio Ltd. (ENTX) filed a definitive proxy statement (DEF 14A) for a Special Meeting of Shareholders on November 24, 2026, seeking approval of eight proposals, five of which stem from the July 2026 private placement led by BVF Partners L.P. that raised approximately $275 million in gross proceeds. The company states the financing is expected to fully fund the Phase 3 registrational program of EB613 and extend cash runway into 2030. The filing also reports the share price declined from $2.28 at December 31, 2024 to $1.94 at December 31, 2025, even as it rose from $0.60 at December 31, 2023, so the stock's trajectory is mixed across the period.

• · Special Meeting scheduled for November 24, 2026 at 08:00 AM Eastern Time in Jerusalem, Israel
• · Record date for voting eligibility is October 1, 2026; internet voting closes 11:59 p.m. ET on November 23, 2026
• · Five 'Supported Proposals' (Proposals 1-5) derive from private placement agreements: 2018 Plan increase, one-time CEO grant, and one-time grants to CFO, COO, and CRO
• · Board unanimously recommends voting FOR all eight proposals
• · Private placement publicly announced July 27, 2026 and closed July 28, 2026
• · Non-PEO NEOs were Hillel Galitzer and Dana Yaacov-Garbeli (2024) and Hillel Galitzer and Gregory Burshtein (2025)
• · Filing is designated 'No fee required' and marked as a Definitive Proxy Statement

14-10-2026

FACT II Acquisition Corp., a Cayman Islands SPAC, has called an extraordinary general meeting for November 10, 2026 to seek shareholder approval for a special resolution extending its deadline to complete an initial business combination from November 27, 2026 to November 25, 2027. Shareholders may redeem Public Shares regardless of how they vote; the estimated redemption price was approximately $10.78 per share versus a closing market price of $10.74 on October 9, 2026. If the extension is not approved and no business combination is completed, the company will redeem public shares and liquidate.

• · Shareholder meeting date: November 10, 2026 at 10:00 a.m. ET (in person at Paul Hastings LLP, New York, or virtually); in-person attendance must be reserved by November 6, 2026
• · Record date for voting: September 29, 2026
• · Extension Amendment Proposal requires a special resolution (at least two-thirds of votes cast by holders of Ordinary Shares); Adjournment Proposal requires an ordinary resolution (simple majority)
• · Redemption rights apply to Public Shares held by public shareholders, excluding the sponsor entities, pre-IPO shareholders, and directors and officers
• · The Articles Amendment will not be implemented if redemptions would reduce net tangible assets below $5,000,001
• · If the extension fails and no business combination closes, redemption of Public Shares occurs within ten business days, and warrants expire worthless with no trust distribution
• · The Adjournment Proposal is only put to a vote if insufficient votes exist for the extension or if redemptions would breach Nasdaq continued listing requirements
• · The board recommends voting FOR both proposals

14-10-2026

Nephros, Inc. has filed its DEF 14A proxy statement soliciting stockholder votes for its virtual Annual Meeting of Stockholders on Wednesday, November 25, 2026, at 11:00 a.m. Eastern Time. The proxy materials, including the Annual Report on Form 10-K for the year ended December 31, 2025, are being mailed on or about October 12, 2026, to holders of record as of September 30, 2026, when 10,870,004 common shares were outstanding. The excerpt provided covers only the solicitation and voting logistics; the specific proposals to be voted on are not included in this excerpt.

• · Annual Meeting is virtual-only, accessible via virtualshareholdermeeting.com/NEPH2026, requiring a control number from the proxy card or voting instruction form
• · Voting may be done by mail, telephone, or Internet without attending the virtual meeting
• · Proxy materials are available at www.proxyvote.com; stockholders may elect electronic delivery of future materials

14-10-2026

Amesite Inc. (AMST) filed a definitive proxy statement on October 14, 2026 for its virtual Annual Meeting of Stockholders on December 10, 2026 at 10:00 a.m. ET. Stockholders will vote on six proposals: election of two Class III directors, ratification of Novogradac & Company LLP as auditor for fiscal year ending June 30, 2027, a reverse stock split at a ratio between 1-for-2 and 1-for-250, authority to issue securities in non-public offerings above 19.99% dilution at prices below the Nasdaq minimum for up to $25 million in aggregate proceeds, an advisory say-on-pay vote, and an advisory vote on say-on-pay frequency. The record date is October 13, 2026.

• · Proposal 3 gives the Board discretion over whether and at what ratio (1-for-2 to 1-for-250) to effect a reverse split, to be completed within one year of stockholder approval
• · Proposal 4 would permit non-public offerings exceeding 19.99% dilution at prices below the Nasdaq minimum, within one year of approval, subject to limitations
• · Proxy materials are distributed via Notice and Access; most holders receive a Notice of Internet Availability rather than paper copies
• · The Company's fiscal year ends June 30; the annual report on Form 10-K for FY ended June 30, 2026 accompanies the materials
• · Company's principal address is listed as Detroit, Michigan (proxy), while the EDGAR business address is Ann Arbor, Michigan

14-10-2026

Transcontinental Realty Investors (TCI) filed a definitive proxy statement (DEF 14A) on October 14, 2026, for an annual stockholder meeting with a conformed period of report of November 11, 2026. The filing covers corporate governance matters, including Board composition (five directors: Henry A. Butler, William J. Hogan, Robert A. Jakuszewski, Ted R. Munselle, and Fernando V. Lara Celis), committee structure, the Board's independence determinations, the nominee selection process, and stockholder householding notices. No financial results or quantitative performance data are presented in the excerpt provided.

• · Board determined Butler, Lara Celis, Munselle, Jakuszewski, and Hogan are independent under Corporate Governance Guidelines following the December 2025 annual independence review
• · Ted R. Munselle was designated Presiding Director in December 2025 by non-management directors, serving until this annual meeting
• · Munselle is designated an 'audit committee financial expert' under SEC rules
• · Company's Investor Relations contact: 800-400-6407; headquarters at 1603 LBJ Freeway, Suite 800, Dallas, TX 75234
• · Filing references the 'YSE' abbreviation for the NYSE, which appears to be a typographical error in the source

14-10-2026

Wave Life Sciences, Inc. (WVE) filed its DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held November 12, 2026 at 11:30 a.m. ET in Cambridge, MA. The meeting was postponed from its historical August timing following the August 7, 2026 redomiciliation, under which Wave Life Sciences, Inc. became the ultimate parent of the group previously headed by Wave Life Sciences Ltd. (Singapore). Stockholders of record as of October 8, 2026 (197,228,058 shares outstanding) are asked to vote on director elections, ratification of KPMG LLP for fiscal 2026, an increase in shares available under the Amended and Restated 2021 Equity Incentive Plan, and a non-binding say-on-pay resolution.

• · Annual meeting postponed from its historical August timing to November 12, 2026 due to the August 2026 Redomiciliation
• · Telephone and internet voting for registered holders closes 11:59 p.m. ET on November 11, 2026
• · Proxy materials and 2025 annual report to stockholders expected to be sent on or about October 14, 2026
• · Information for periods before the Redomiciliation relates to predecessor Wave-Singapore
• · Board recommends FOR all director nominees, FOR KPMG ratification, FOR the equity plan increase, and FOR say-on-pay

14-10-2026

Mountain Crest Acquisition Corp. V (MCAGU) has filed a definitive proxy statement for a November 10, 2026 special meeting to vote on extending its business combination deadline from November 16, 2026 to May 16, 2027, and on authorizing adjournment. The extension is needed because management believes the pending business combination with CubeBio Co., Ltd. cannot close before the current deadline. Trust account holdings are approximately $861,864 as of September 14, 2026, with an estimated redemption price of about $11.95 per share versus a last closing price of $13.27, so the stock trades above redemption value, which is a mixed signal for public holders.

• · Special Meeting scheduled for November 10, 2026 at 11:00 a.m. ET (virtual); separate Business Combination Meeting set for November 11, 2026
• · Redemption deadline is November 6, 2026, requiring shares to be tendered to Continental Stock Transfer at least two business days before the meeting
• · Business Combination Agreement with CubeBio was signed August 29, 2024; Form F-4 declared effective September 30, 2026
• · If the extension is not approved and no business combination closes by November 16, 2026, the company will redeem all public shares and dissolve, with no trust distribution on rights, which expire worthless
• · Units are quoted on the OTC Market (MCAGU, MCAG, MCAGR), and PubCo intends to seek Nasdaq or an alternate exchange listing with no assurance of approval
• · Management believes the business combination cannot close before November 16, 2026 but can close before May 16, 2027

14-10-2026

Bowhead Specialty Holdings Inc. has called a virtual special meeting on November 13, 2026 for stockholders to vote on adopting a Merger Agreement dated August 2, 2026 with American Family Mutual Insurance Company, S.I. and its subsidiary Trident Superior Inc., under which Bowhead would become a wholly-owned subsidiary of Parent. Each outstanding common share (other than treasury shares, Parent-held shares, and perfected appraisal shares) would be converted into the right to receive $34.00 in cash. The merger requires approval by a majority of all outstanding shares and a separate majority of 'Subject Stockholders' (excluding Parent, its subsidiaries, and Recused Directors), and the transaction is a 'going private transaction' under SEC rules.

• · Special meeting to be held virtually on November 13, 2026 at 9:00 a.m. Eastern; online check-in begins 8:45 a.m.
• · Merger requires majority approval of all outstanding shares AND majority of Subject Stockholders, a separate minority-style condition that is also a closing condition under the Merger Agreement
• · Non-Recused Directors constitute a quorum of the Board but do not form a separate special committee; they unanimously recommended FOR the Merger Proposal, Compensation Advisory Proposal, and Adjournment Proposal
• · Broker non-votes and non-returned proxies have the same effect as a vote AGAINST the Merger Proposal; all proposals are expected to be non-routine
• · Stockholders who perfect appraisal rights under DGCL Section 262 will have their shares excluded from the cash conversion (see Appraisal Rights section, page 11)
• · Record date and proxy solicitation contact: Innisfree M&A Incorporated, toll-free (877) 825-8971

14-10-2026

American Realty Investors, Inc. (NYSE: ARL) filed its definitive proxy statement on October 14, 2026, for an annual meeting of stockholders with a record/period date of November 11, 2026. The filing covers board composition, committee structure, director independence determinations made in December 2025, the presiding director designation, nominee selection procedures, and stockholder householding rules. The excerpt contains no financial results, executive compensation figures, or dollar amounts.

• · Ted R. Munselle was designated Presiding Director by non-management directors in December 2025, serving until this annual meeting
• · Board affirmatively determined Butler, Lara Celis, Munselle, Jakuszewski and Hogan are independent under Corporate Governance Guidelines and NYSE standards
• · Munselle is qualified as an audit committee financial expert under SEC regulations
• · Filing references an annual report containing audited financial statements, provided to common stockholders (financials themselves not included in excerpt)